Lv11
84 积分 2024-10-02 加入
Benchmarking Complications Associated with Esophagectomy
4小时前
待确认
Tislelizumab combined with nab‐paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two‐cohort, phase 2 trial
7个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
7个月前
已完结
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
8个月前
已完结
Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study
8个月前
已完结
Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study
8个月前
已完结
Minimally invasive versus open esophagectomy; comparing the combined effects of smoking burden and operative approach on outcomes in esophagectomy
8个月前
已完结
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto
8个月前
已完结
Tislelizumab combined with nab‐paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two‐cohort, phase 2 trial
8个月前
已完结
Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study
10个月前
已完结
皖公网安备34019202002308
